Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Northwest Biotherapeutics Inc. -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (52)	8/22/2006 5:43:53 PM
From: John McCarthy	Read Replies (1) \| Respond to of 760

Hi Liz - we are on the same page >>>>>>>>>>>>>> The results were so surprising that the trial was stopped before full accrual, and a pharmaceutical company acquired the rights to the drug. >>>>>>>>>>>>>> as follows: (1) I don't know who they are talking about and will google this side-ways from Sunday (2) WOW - I was thinking no self-respecting pharm or maybe even big pharm would go near a cancer vaccine - THAT issue is behind us <g> (3) more concerned about finding out more about the underlying vaccine ANDERSON has - but don't have a clue as to how to go about it .... (there MUST BE a blurb somewhere about P1 results - No? ) (4) I thought we were in a special niche ... I now feel (after 3 days) we're in a dog-fight .... (5) Lets dumb it down for me - the ANDERSON vaccine (probably) has money (from somebody) to complete a Phase 2 trial ... we DON'T .... driving home I was talking to myself .... (day-dreaming) - could NW be talking to somebody .... because - how do they think they can run this trial without another - $10 million - maybe $15 million am I off-base in thinking this? to close - I will see what I can dig up - but I need a week ... how all is well with you .... regards, John